Infliximab extends the duration until the first surgery in patients with Crohn's disease.
Infliximab extends the duration until the first surgery in patients with Crohn's disease.
复制标题
DOI：
10.1155/2013/879491
复制
发表时间：
2013
影响因子：
--
通讯作者：
Kohgo Y
中科院分区：
文献类型：
--
作者：
Sakatani A;Fujiya M;Ito T;Inaba Y;Ueno N;Kashima S;Tominaga M;Moriichi K;Okamoto K;Tanabe H;Ikuta K;Ohtake T;Kono T;Furukawa H;Ashida T;Kohgo Y
背景/目标。虽然生物药物可用于缓解克罗恩病（CD）患者的疾病活动性和预防腹部手术，但尚不清楚在无腹部手术史的CD患者中使用生物药物是否合适。我们评估了英夫利西单抗和其他因素对延长CD患者首次手术持续时间的长期影响。方法.对104例CD患者的临床资料进行回顾性分析。根据人口统计学因素和治疗方法，对首次手术前的累积非手术率进行了研究。结果104例CD患者的50%非手术时间间隔为107个月。单变量分析的结果显示，女性、CD结肠炎类型和皮质类固醇、免疫调节剂或英夫利西单抗给药是估计可改善累积非手术率的因素。多变量分析显示，结肠炎类型和英夫利西单抗给药是与无腹部手术史的CD患者首次手术间隔延长相关的独立因素。结论.这项研究表明，英夫利西单抗治疗延长了没有腹部手术史的CD患者首次手术的持续时间。因此，在患者接受腹部手术前早期使用英夫利西单抗是合适的。
Background/Aims. While biological drugs are useful for relieving the disease activity and preventing abdominal surgery in patients with Crohn's disease (CD), it is unclear whether the use of biological drugs in CD patients with no history of abdominal surgery is appropriate. We evaluated the effects of infliximab and other factors on extending the duration until the first surgery in CD patients on a long-term basis. Methods. The clinical records of 104 CD patients were retrospectively investigated. The cumulative nonoperation rate until the first surgery was examined with regard to demographic factors and treatments. Results. The 50% nonoperative interval in the 104 CD patients was 107 months. The results of a univariate analysis revealed that a female gender, the colitis type of CD, and the administration of corticosteroids, immunomodulators, or infliximab were factors estimated to improve the cumulative nonoperative rate. A multivariate analysis showed that the colitis type and administration of infliximab were independent factors associated with a prolonged interval until the first surgery in the CD patients with no history of abdominal surgery. Conclusions. This study suggests that infliximab treatment extends the duration until the first surgery in CD patients with no history of abdominal surgery. The early use of infliximab before a patient undergoes abdominal surgery is therefore appropriate.
登录
查看更多内容
影响因子：
8
作者：
Dignass, A.;Van Assche, G.;Travis, S. P. L.
通讯作者：
Travis, S. P. L.
影响因子：
29.4
作者：
Hanauer, SB;Sandborn, WJ;Pollack, P
通讯作者：
Pollack, P
影响因子：
158.5
作者：
PRESENT, DH;KORELITZ, BI;PASTERNACK, BS
通讯作者：
PASTERNACK, BS
影响因子：
29.4
作者：
Colombel, Jean-Frederic;Sandborn, William J.;Pollack, Paul F.
通讯作者：
Pollack, Paul F.
影响因子：
24.5
作者：
Campieri, M;Ferguson, A;Weir, DG
通讯作者：
Weir, DG